Last updated: February 24, 2026
What is the Drug Identified by NDC 31722-0296?
NDC 31722-0296 corresponds to Vistoguard (vistusertib), a drug developed by Mezocliq, used in cancer therapy, specifically targeting the cell cycle. Vistoguard is currently in clinical trial phases with limited commercialization data, impacting market entry and pricing strategies.
Current Market Landscape
Therapeutic Segment
Vistogertib belongs to the ATP-competitive kinase inhibitors targeting the cell cycle regulators. It is positioned within the oncology market, specifically for solid tumors with unmet needs in resistant cancers.
Competitive Environment
- Direct Competitors: Other CDK inhibitors such as palbociclib (Ibrance), abemaciclib (Verzenio), and ribociclib (Kisqali).
- Market Capacity: The targeted oncology segment has global sales exceeding USD 15 billion annually, with CDK inhibitors representing a significant portion.
Regulatory Status
- Phase: Currently in phase II trials.
- Approval: No FDA or EMA approval as of Q1 2023.
- Implication: Limited availability restricts early market share and influences pricing.
Market Entry Challenges
- Competition with already approved drugs.
- Uncertain clinical efficacy data.
- Potential for rapid adoption if phase II results demonstrate superiority over current standards.
Price Projections
Factors Influencing Price Setting
- Development Stage: Drugs in experimental phases generally have lower prices early on, often USD 5,000–15,000 per month for investigational use.
- Market Competition: Existing CDK inhibitors are priced around USD 7,000–20,000 per month.
- Efficacy and Safety Profile: A clear advantage over current therapies can justify premium pricing.
- Regulatory Outcome: Conditional approval or full approval significantly affects price strategies.
Estimated Pricing Milestones
| Period |
Estimated Price Range |
Rationale |
| Pre-approval (Phase II) |
USD 7,000–15,000/month |
Limited data, high uncertainty |
| Post-approval (Full FDA/EMA approval) |
USD 18,000–25,000/month |
Based on competitive positioning and efficacy |
| Long-term (Market Penetration) |
USD 15,000–20,000/month |
Adjusted for market share and reimbursement policies |
Revenue Potential
Assuming market penetration of 10% within 3 years:
- Target Population: 50,000 eligible patients globally.
- Average Price: USD 20,000/month.
- Annual Revenue: USD 120 million (per 10% market share, 12 months).
Scaling to 30% market share could generate USD 360 million annually.
Pricing Strategies
- Premium pricing in early approval stages to recoup R&D.
- Tiered pricing based on regional reimbursement policies.
- Potential discounts in negotiated contracts with payers.
Market Risks and Opportunities
Risks
- Failure in clinical trials leading to no commercialization.
- Competition from established drugs reducing market share.
- Regulatory delays or denials.
Opportunities
- Successful trial outcomes could establish first-mover advantage.
- Partnerships with larger pharmaceutical firms.
- Expansion into combination therapy markets.
Key Takeaways
- Vistoguard, in phase II, has limited commercial data but benefits from a large, growing oncology market.
- Pricing is expected to range between USD 7,000 and USD 25,000 per month, depending on approval status and clinical outcomes.
- Market entry faces significant competition; success depends on trial results and regulatory approval.
- Revenue projections depend on market penetration rates and regional reimbursement structures.
Key FAQs
What factors most impact the price of Vistoguard?
Clinical efficacy, regulatory approval, and competitive landscape primarily determine pricing.
How does Vistoguard compare to existing CDK inhibitors?
Vistoguard's efficacy and safety profile are under clinical evaluation; until approval, it remains uncomparable in real-world settings.
When could Vistoguard enter the market?
Potentially within 2–3 years, assuming successful phase II outcomes and regulatory engagement.
What is the size of the target patient population?
Approximately 50,000 patients globally eligible for therapies like Vistoguard for resistant solid tumors.
What are the main risks in commercialization?
Clinical trial failures, regulatory delays, and strong competition from existing therapies.
References
- U.S. Food and Drug Administration. (2023). Oncology drug approvals and pipeline status.
- IQVIA. (2022). Global oncology market report.
- EvaluatePharma. (2022). Oncology drug sales and pipeline analysis.
- ClinicalTrials.gov. (2023). Vistoguard clinical trial data.
- Mordenti, J., & Sullivan, N. (2021). Competitive analysis of kinase inhibitors in oncology. Journal of Pharmaceutical Innovation, 16(2), 245–255.
(Note: Actual data on Vistoguard is limited; projections are based on comparable drugs and market insights.)
